Publications en collaboration avec des chercheurs de Hospital Vall d'Hebron (8)

2020

  1. A randomized double-blind phase II study evaluating the role of maintenance therapy with cabozantinib in high-grade uterine sarcoma after stabilization or response to doxorubicin ± ifosfamide following surgery or in metastatic first line treatment (EORTC62113)

    International Journal of Gynecological Cancer, Vol. 30, Núm. 10, pp. 1633-1637

2019

  1. Multicenter retrospective study to evaluate the impact of trabectedin plus pegylated liposomal doxorubicin on the subsequent treatment in women with recurrent, platinum-sensitive ovarian cancer

    Anti-Cancer Drugs, Vol. 30, Núm. 6, pp. 628-635

2017

  1. Phase II randomized study of PM01183 versus topotecan in patients with platinum-resistant/refractory advanced ovarian cancer

    Annals of Oncology, Vol. 28, Núm. 6, pp. 1280-1287

2016

  1. ESMO-ESGO-ESTRO consensus conference on endometrial cancer: Diagnosis, treatment and follow-up

    Annals of Oncology, Vol. 27, Núm. 1, pp. 16-41

2012

  1. Trabectedin in pre-treated patients with advanced or metastatic soft tissue sarcoma: A phase II study evaluating co-treatment with dexamethasone

    Investigational New Drugs, Vol. 30, Núm. 2, pp. 729-740

2010

  1. Prognostic time dependence of deletions affecting codons 557 and/or 558 of KIT gene for relapse-free survival (RFS) in localized GIST: A Spanish Group for Sarcoma Research (GEIS) Study

    Annals of Oncology, Vol. 21, Núm. 7, pp. 1552-1557

2003

  1. Doxorubicin in combination with fluorouracil and cyclophosphamide (i.v. FAC regimen, day 1, 21) versus methotrexate in combination with fluorouracil and cyclophosphamide (i.v. CMF regimen, day 1, 21) as adjuvant chemotherapy for operable breast cancer: A study by the GEICAM group

    Annals of Oncology, Vol. 14, Núm. 6, pp. 833-842

1998

  1. Phase II trial of first-line high-dose ifosfamide in advanced soft tissue sarcomas of the adult: A study of the Spanish Group for Research on Sarcomas (GEIS)

    Annals of Oncology, Vol. 9, Núm. 8, pp. 871-876